Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 filing contains only the signature block, not operating results or financial metrics.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 filing contains only the signature block, not operating results or financial metrics
- CFO Alex Kim signed the report for Standard BioTools on August 5, 2026
Item 7.01 · Regulation FD Disclosure
- Regulation FD disclosure incorporates the “Full Year 2026 Revenue Outlook” into the filing
- Revenue outlook details appear in the referenced exhibit, alongside company background and forward-looking-risk language
- Investors should assess the outlook against execution risks and the accompanying disclaimer before updating forecasts
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $20.1M, down 7.6% YoY amid weaker consumables, instruments, and services demand
- Adjusted EBITDA loss improved 84% to $2.5M, supported by 50% lower non-GAAP operating expenses
- GAAP net loss widened to $21.5M, driven by $14.7M transaction and integration expenses
- Cash, investments, and restricted cash reached $541.1M, strengthened by $388.2M business-sale proceeds
- Treeline merger remains targeted for completion before year-end 2026; full-year revenue outlook withdrawn.pending transaction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.